Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High Risk Cancer Gene Discovered

By LabMedica International staff writers
Posted on 30 Jan 2012
A gene that plays a key role in the development of esophageal cancer has been discovered and characterized. More...


The gene is thought to play a role in the more common, noninherited form of esophageal cancer, revealing a new target for treating this aggressive type of malignancy.

A study led by scientists at Queen Mary's School of Medicine and Dentistry (London, UK) investigated families who suffer a rare inherited condition making them highly susceptible to the disease and found that a fault in a single gene was responsible. They concentrated on three families with a hereditary condition called tylosis with esophageal cancer. This condition affects the skin and mouth and sufferers have a 95% chance of developing esophageal cancer by the age of 65.

The study revealed that all three families carried a faulty version of a gene called the rhomboid family member 2 (RHBDF2). This gene plays an important role in how cells that line the esophagus, and cells in the skin, respond to injury. When the gene is functioning normally, it ensures that cells grow and divide in a controlled fashion to help heal a wound. However, in tylosis patients' cells, and in cells from esophageal cancers, the gene malfunctions. This allows cells to divide and grow uncontrollably, causing cancer.

David Kelsell, PhD, a professor at Queen Mary, said "In studying this relatively rare condition, we have made an important discovery about a cancer that is all too common. Finding a genetic cause for this aggressive cancer, and understanding what that gene is doing, is an enormous step forward. By analyzing the complex biology which causes a particular type of cancer we begin to understand which treatments might be effective and also which treatments are unlikely to help." Esophageal cancer or cancer of the gullet affects more than 8,000 people each year in the UK and rates are rising. It is more common in the UK than anywhere else in Europe.

Related Links:
Queen Mary's School of Medicine and Dentistry


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.